XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on oncology drug development that reached U.S. public markets through a SPAC merger, with its annual 10-K report filed with the SEC on June 1, 2020 under accession number 0001213900-20-013743. The company operates in the healthcare and life sciences sector, developing cancer therapeutics, and its post-merger public status reflects the broader wave of China-linked biopharma firms accessing U.S. equity markets via blank-check vehicles during that period. The filing represents the company's position as a combined entity following its de-SPAC transaction. For complete filing history, merger details, sponsor information, and deal timeline data on Xynomic Pharmaceuticals Holdings and thousands of other SPAC transactions, sign up for full access at SpacDesk.